A Randomised Controlled Feasibility Trial of Immersive Virtual Reality Treatment with Cognitive Behaviour Therapy for Specific Phobias in Young People with Autism Spectrum Disorder.


Journal

Journal of autism and developmental disorders
ISSN: 1573-3432
Titre abrégé: J Autism Dev Disord
Pays: United States
ID NLM: 7904301

Informations de publication

Date de publication:
May 2019
Historique:
pubmed: 16 2 2019
medline: 20 6 2019
entrez: 16 2 2019
Statut: ppublish

Résumé

We examined the feasibility and acceptability of using an immersive virtual reality environment (VRE) alongside cognitive behaviour therapy (CBT) for young people with autism experiencing specific phobia. Thirty-two participants were randomised to treatment or control. Treatment involved one session introducing CBT techniques and four VRE sessions, delivered by local clinical therapists. Change in target behaviour was independently rated. Two weeks after treatment, four treatment participants (25%) and no control participants were responders; at 6 months after treatment, six (38%) treatment and no control participants were responders. At 6 months post-treatment, symptoms had worsened for one treatment and five control (untreated) participants. Brief VRE exposure with CBT is feasible and acceptable to deliver through child clinical services and is effective for some participants.

Identifiants

pubmed: 30767156
doi: 10.1007/s10803-018-3861-x
pii: 10.1007/s10803-018-3861-x
pmc: PMC6484088
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1912-1927

Subventions

Organisme : Department of Health
ID : PB-PG-0213-30067
Pays : United Kingdom
Organisme : Research for Patient Benefit Programme
ID : PB-PG-0213-30067

Références

Br J Psychiatry. 1999 Nov;175:444-51
pubmed: 10789276
J Autism Dev Disord. 2002 Aug;32(4):299-306
pubmed: 12199134
J Am Acad Child Adolesc Psychiatry. 2003 Dec;42(12):1443-50
pubmed: 14627879
Behav Res Ther. 2004 Jul;42(7):813-39
pubmed: 15149901
Child Psychiatry Hum Dev. 2005 Fall;36(1):3-26
pubmed: 16049642
J Child Psychol Psychiatry. 2005 Nov;46(11):1152-60
pubmed: 16238662
Lancet. 2006 Jul 15;368(9531):210-5
pubmed: 16844490
J Autism Dev Disord. 2006 Oct;36(7):849-61
pubmed: 16845581
J Autism Dev Disord. 2007 Mar;37(3):589-600
pubmed: 16900403
Child Care Health Dev. 2007 Jan;33(1):28-39
pubmed: 17181750
J Behav Ther Exp Psychiatry. 2008 Sep;39(3):250-61
pubmed: 17720136
J Am Acad Child Adolesc Psychiatry. 2008 Aug;47(8):921-9
pubmed: 18645422
Dev Neurorehabil. 2010 Feb;13(1):53-63
pubmed: 20067346
Top Lang Disord. 2007 Jul 1;27(3):226-241
pubmed: 20072702
J Autism Dev Disord. 2010 Sep;40(9):1080-93
pubmed: 20177765
Clin Child Fam Psychol Rev. 2011 Sep;14(3):302-17
pubmed: 21735077
J Autism Dev Disord. 2013 Jan;43(1):34-44
pubmed: 22570145
J Autism Dev Disord. 2013 Apr;43(4):851-9
pubmed: 22895777
Neuropsychology. 2014 Jan;28(1):55-67
pubmed: 24015827
J Autism Dev Disord. 2014 Oct;44(10):2450-63
pubmed: 24803366
PLoS One. 2014 Jul 02;9(7):e100374
pubmed: 24987957
Child Psychiatry Hum Dev. 2015 Aug;46(4):533-47
pubmed: 25246292
Psychiatry Res. 2016 Feb 28;236:189-195
pubmed: 26795129
J Child Psychol Psychiatry. 2017 Apr;58(4):474-503
pubmed: 27943285
Psychol Med. 2017 Oct;47(14):2393-2400
pubmed: 28325167
Harv Rev Psychiatry. 2017 May/Jun;25(3):103-113
pubmed: 28475502
Curr Psychiatry Rep. 2017 Jul;19(7):42
pubmed: 28540594
J Child Psychol Psychiatry. 2018 Nov;59(11):1180-1191
pubmed: 29687457
Arch Gen Psychiatry. 1983 Nov;40(11):1228-31
pubmed: 6639293
Behav Res Ther. 1983;21(6):685-92
pubmed: 6661153
Behav Res Ther. 1997 Feb;35(2):165-73
pubmed: 9046680
Behav Res Ther. 1998 May;36(5):545-66
pubmed: 9648330

Auteurs

Morag Maskey (M)

Institute of Neuroscience, Sir James Spence Institute Level 3, Royal Victoria Infirmary, Newcastle University, Newcastle upon Tyne, NE1 4LP, UK.

Jacqui Rodgers (J)

Institute of Neuroscience, Sir James Spence Institute Level 3, Royal Victoria Infirmary, Newcastle University, Newcastle upon Tyne, NE1 4LP, UK.

Victoria Grahame (V)

Complex Neurodevelopmental Disorders Service, Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.
Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.

Magdalena Glod (M)

Institute of Neuroscience, Sir James Spence Institute Level 3, Royal Victoria Infirmary, Newcastle University, Newcastle upon Tyne, NE1 4LP, UK.

Emma Honey (E)

Complex Neurodevelopmental Disorders Service, Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.

Julia Kinnear (J)

Newcastle University, Newcastle upon Tyne, UK.

Marie Labus (M)

Business Development and Enterprise, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Jenny Milne (J)

Tees Esk and Wear Valley NHS Foundation, Trust, UK.

Dimitrios Minos (D)

Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.

Helen McConachie (H)

Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.

Jeremy R Parr (JR)

Institute of Neuroscience, Sir James Spence Institute Level 3, Royal Victoria Infirmary, Newcastle University, Newcastle upon Tyne, NE1 4LP, UK. jeremy.parr@ncl.ac.uk.
Complex Neurodevelopmental Disorders Service, Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK. jeremy.parr@ncl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH